Explore UCD

UCD Home >

Trials Directory

A full listing of all our trials are shown below. Use any of the filter methods in this box to search and show only trials of interest to you.

Profile photo of A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study-HI-PEITHO.

A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study-HI-PEITHO.

Principal Investigator: Dr Umer Salati

This study will assess two treatment options for pulmonary embolism (a clot in the blood vessels in your lung). One treatment using ultrasound guided thrombolysis and anticoagulation (procedures that break up blood clots). Compared with treatment with anticoagulation alone. Mortality (death), cardiorespiratory decompensation (reduced heart function) or collapse within 7 days will be assessed and compared.

Key Eligibility Critera: Age 18-80 years inclusive. Confirmed pulmonary embolism.

Clinical Area:

Condition:

Profile photo of Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy:OVHIPEC-2

Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy:OVHIPEC-2

Principal Investigator: Professor Donal Brennan

This study is a multicentre, open label (participants know their treatment) trial. Patients with FIGO stage III epithelial ovarian cancer, eligible for surgery to reduce the amount of cancer in their body, will be included. They will be randomised to receive surgery with or without hyperthermic intraperitoneal chemotherapy (where a dose of heated chemotherapy is provided after surgery).

Key Eligibility Critera: Age 18 years. stage III primary epithelial ovarian, fallopian tube, or extra-ovarian
cancer, treated with primary complete cytoreduction.

Clinical Area:

Condition:

Profile photo of A randomised, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.

A randomised, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.

Principal Investigator: Professor Chris McGuigan

This study will evaluate the effectiveness, safety and tolerability of a drug, remibrutinib, as a treatment for patients with relapsing multiple sclerosis.

Key Eligibility Critera: Age 18-55 years inclusive. Daignosis of relapsing multiple sclerosis

Clinical Area:

Condition:

Profile photo of SWIFT - A randomised, controlled, parellel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity.

SWIFT - A randomised, controlled, parellel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity.

Principal Investigator: Prof Mary Horgan

The prevalence of obesity is rising worldwide, both in low- and high-income countries, including in people living with HIV (PLWH). Semaglutide is a drug whose effectiveness in achieving weight loss in PLWH and obesity is still unexplored. The aim of this study is to figure out the effectiveness and safety of semaglutide, in achieving greater weight loss compared to diet and exercise alone, in a group of PLWH and obesity. This study aims to explore the effect of semaglutide on the immune function, markers of immune activation (helps our immune system respond to infections), viral reservoir (a safe hiding spot in the body for viruses to stay inactive or dormant), markers of glucose (blood sugar) and lipid (fatty compound) metabolism and gut microbiome (microorganisms that live in your digestive tract). The treatment stage of the trial will last for 28 weeks, with follow up until 40 weeks.

Key Eligibility Critera: ≥ 18 years old; HIV-1 antibody positive; BMI ≥27kg/m & hypertension.

Clinical Area:

Condition:

Profile photo of MPOX-VAX Study

MPOX-VAX Study

Principal Investigator: Prof Mary Horgan

This is a prospective clinical trial (a study where individuals are followed over time) examining the immune response of participants receiving Modified Vaccinia Ankara (MVA), a vaccine for the prevention of monkeypox (Mpox) infection. Participants may receive MVA 0.1ml intradermally (a shallow injection) or MVA 0.5ml subcutaneously (a deeper injection) on one or two occasions as part of routine clinical care. Participants will attend 5 follow up visits over 48 weeks after their first dose of MVA. The main aim of this trial is to find out the rate of change of (durability), and factors associated with, MVA-specific antibodies (proteins that help remove infection) after 48 weeks post vaccination with MVA.

Key Eligibility Critera: ≥ 18 years old, Eligible for 1 or 2 doses of MVA for Mpox prevention as per NIAC guidelines

Clinical Area:

Condition:

Profile photo of HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

Principal Investigator: Professor Niall Mahon

This study aims to determine if ziltivekimab can be used to treat people living with heart failure and inflammation in reducing the risk of cardiovascular death and heart failure events. Participants will receive either ziltivekimab or placebo (a pill with no active drug ingredient). The study drug will be given through monthly injections, using either a pre-filled syringe or a pen-injector. The trial is expected to last for up to 4 years. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.

Key Eligibility Critera: Diagnosis of heart failure ≥ 18 years old

Clinical Area:

Condition:

Profile photo of Cirrhosis-Acute Kidney Injury Cohort Study

Cirrhosis-Acute Kidney Injury Cohort Study

Principal Investigator: Associate Professor Michael Reardon WGH

The aim of this study is to figure out the ability of novel urinary biomarkers (which tell us information about your health) to predict response/progression of acute kidney injury in patients with liver disease. This Observational Non-Interventional Cohort Study (a study where people are observed over time but not given a study drug/treatment/procedure) will seek to determine if urine biomarkers of kidney injury help to predict the course and outcomes of acute kidney injury with standard medical care.

Key Eligibility Critera: Hospitalised with Diagnosis of Cirrhosis and a new Acute Kidney Injury

Clinical Area:

Condition:

Find out more and take a look at our projects:

Taking Part in a Clinical Trial
Taking Part in a Clinical Trial
Collaborate with the Clinical Trials Unit
Collaborate with the Clinical Trials Unit
Become a Trials Expert
Become a Trials Expert
About Us
About Us

Contact the UCD Clinical Research Centre

Newman Building, University College Dublin, Belfield, Dublin 4, Ireland.
T: +353 1 716 7777 |